Lung Cancer
Commentary
Discontinuing immunotherapy: Is the infusion bag half empty or half full?
Clinical trials of immunotherapy or chemoimmunotherapy have generally terminated treatment in nonprogressing patients after 2 years.
From the Journals
Buzz kill: Lung damage looks worse in pot smokers
Emphysema was significantly more common among smokers (75%) than among nonsmokers, a new study finds.
Conference Coverage
How AI is, or will soon be, relevant in radiation oncology
Radiation oncologists at ASTRO 2022 discuss practical applications of AI, and new research findings.
From the Journals
Chronic stress, especially race related, may hasten cancer death
High allostatic load was associated with an 80% increased risk of cancer death among all study participants.
From the Journals
Third COVID booster benefits cancer patients
For the first time, researchers have quantified the benefits of boosters for COVID-19 in cancer patients.
From the Journals
Durvalumab combinations show tentative promise in NSCLC
Phase 2 study indicates improved survival and objective response rate when combined with other immunotherapies.
From the Journals
Mutation burden predicts ICI response in lung cancer
Novel biomarker combined with PD-L1 expression could indicate selection of immunotherapy and avoid chemotherapy toxicities in some patients.
Conference Recap
Key Data on Early Non–Small Cell Lung Cancer From ESMO 2022
Osimertinib dosing periods, the use of ctDNA to predict recurrence, and the role of air pollution in promoting lung cancer are among...
Lung Cancer Updates
Had my patient come in today, we may have had other options
FDA’s approval of trastuzumab deruxtecan is a game-changer for NSCLC patients with HER alterations.
Diminutio
Cancer as a full contact sport
The complexity of cancer care has long necessitated a team approach to planning cancer treatment.
Lung Cancer Updates
In progressive lung cancer second biopsies may be the norm now
Many years after their discovery, we finally have a new string of EGFR-TKI approvals for NSCLC.